A Phase 1 interventional study of Gepotidacin in Infections, Bacterial, sponsored by GlaxoSmithKline. Completed at 2 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-04-12.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing gepotidacin in Bacterial Infections — 1 open to participants now, 1 under way, none of them phase 3. gepotidacin · Bacterial Infections.
Among the 11 studies testing gepotidacin in Bacterial Infections, this one is the 8th largest by enrollment, is one of 2 that started in 2018, is one of 9 in phase 1, and was the 6th registered.
585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.
Browse Bacterial Infections studies →1 of the 11 studies testing gepotidacin in Bacterial Infections is open now, in 1 country. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States
Ages 2–11
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2018.
This study's enrollment of 25 is below the median of 84 across 383 interventional studies indexed under Bacterial Infections.
Median enrollment 34 across the 11 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 11 have an industry lead sponsor. The 2 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
35 studies in Bacterial Infections by GlaxoSmithKline: 1 open now, 1 under way, none of them phase 3. Of 29 finished, 13 (45%) have results posted.
Among the 35 studies in Bacterial Infections by GlaxoSmithKline, this one is the 20th largest by enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2018, is one of 28 in phase 1, and was the 30th registered.
GlaxoSmithKline’s Bacterial Infections studies by the year they started, since 2005.
1 of the studies testing gepotidacin in Bacterial Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07371429GlaxoSmithKlineA Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis Antibiotics | 2027-08-23 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing gepotidacin in Bacterial Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 35 in Bacterial Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a two-part study which will evaluate the PK, safety, and tolerability of a single 1500 milligram (mg) oral dose of gepotidacin in subjects with normal hepatic function and in subjects with mild, moderate, and severe hepatic impairment. In Part 1, subjects with moderate hepatic impairment and subjects with normal hepatic function will be enrolled. Matching subjects with normal hepatic function in Part 1 (Group D), will be enrolled following the completion of all Day 3 assessments of the respective matched, hepatically impaired subject. In Part 2, subjects with mild (optional) and severe hepatic impairment and subjects with normal hepatic function will be enrolled concurrently based on the PK, safety, and tolerability data of Part 1. Subjects with mild hepatic impairment, may be studied if there is a significant difference in PK between subjects with moderate hepatic impairment and subjects with normal hepatic function. Subjects with severe hepatic impairment, will be studied in Part 2, provided that, the PK objectives are achieved in Part 1. A totals of 48 subjects, are planned to be enrolled in the study. The study duration is approximately of 44 days from Screening to Follow-up visit. The results from this study will enable the development of appropriate dosing recommendations in subjects with impaired hepatic function.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The eligible subjects, with normal hepatic function, in this arm will receive a single oral dose of gepotidacin as 1500 milligram (mg), administered as 2 × 750 mg tablets on Day 1.
Drug: Gepotidacin
The subjects in this arm, will be the one's with a Child-Pugh score of 7 to 9, and will receive a single oral dose of gepotidacin, as 1500 mg, administered as 2 × 750 mg tablets on Day 1.
Drug: Gepotidacin
The subjects in this arm, will be the one's with a Child-Pugh score of 5 to 6, and will receive a single oral dose of gepotidacin, as 1500 mg, administered as 2 × 750 mg tablets on Day 1. This will be optional arm.
Drug: Gepotidacin
The subjects in this arm, will be the one's, with a Child-Pugh score of 7 to 9, and will receive a single oral dose of gepotidacin, as 1500 mg, administered as 2 × 750 mg tablets, on Day 1.
Drug: Gepotidacin
The eligible subjects, with normal hepatic function, will be matching with those enrolled in Part1, and will receive a single oral dose of gepotidacin as 1500 mg, administered as 2 × 750 mg tablets on Day 1.
Drug: Gepotidacin
It is an immediate-release tablet (1500 mg (2 x 750 mg), containing gepotidacin (free base) an inactive formulation excipients.
Area Under the Plasma Concentration-time Curve (AUC) From Time Zero (Pre-dose) Extrapolated to Infinity (AUC[0-inf]) for Plasma Gepotidacin
Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate pharmacokinetic (PK) parameters. PK parameter population consist of all participants in the PK Population, for whom valid and evaluable PK parameters were derived. This population was used in the assessment and characterization of PK parameters.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose
Maximum Observed Concentration (Cmax) for Plasma Gepotidacin
Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate PK parameters.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose
AUC From Time 0 to the Time of the Last Quantifiable Concentration (AUC [0-t]) for Plasma Gepotidacin
Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate PK parameters.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose
Time to First Occurrence (Tmax) of Cmax for Plasma Gepotidacin
Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate PK parameters.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose
Lag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) for Plasma Gepotidacin
Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate PK parameters.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose
Apparent Oral Clearance (CL/F) for Plasma Gepotidacin
Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate PK parameters.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose
Apparent Volume of Distribution of the Terminal Phase (Vz/F) for Plasma Gepotidacin
Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate PK parameters.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose
Terminal-phase Rate Constant (Lambda_z) for Plasma Gepotidacin
Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate PK parameters.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose
Terminal Phase Half Life (t1/2) for Plasma Gepotidacin
Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate PK parameters.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose
Number of Participants With Abnormal Electrocardiogram (ECG) Findings
Single 12-lead ECG was obtained in a semi-supine position after 5 minutes rest using an ECG machine. Safety Population consists of all participants who received at least 1 dose of study drug and had at least one postdose safety assessment. Number of participants with abnormal-clinically significant and abnormal-not clinically significant values has been presented. Absolute QTc Interval \>450 milliseconds (msec), absolute PR interval \<110 msec and absolute QRS interval \<75 msec was considered as clinically significant ECG findings.
Time frame: 1.5 hours, 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose
Change From Baseline Values in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Vital signs were measured in a semi-supine position after 5 minutes rest. Baseline is defined as Day 1 (Pre-Dose). Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at 1.5 hours, 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose
Change From Baseline Values in Heart Rate
Vital signs was measured in a semi-supine position after 5 minutes rest. Baseline is defined as Day 1 (Pre-Dose). Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at 1.5 hours, 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, and 48 hours post dose
Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgment.
Time frame: Up to Day 15
Number of Participants With Toxicity Grading 3 or Higher for Clinical Chemistry Parameters
Blood samples were collected to measure the number of participants with toxicity grades higher than 3 or 4, for urea, Creatine kinase (CK), creatinine, glucose, sodium, potassium, calcium, Aspartate Aminotransferase, (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) levels, total and direct bilirubin, total protein, and albumin.
Time frame: Up to Day 15
Change From Baseline Values for Clinical Chemistry Parameters: ALT, ALP, AST and CK
Blood samples were collected to analyze clinical chemistry parameters including: ALT, ALP, AST and CK. Baseline is defined as Day 1 (Pre-Dose). Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline and at Day 2
Change From Baseline Values for Clinical Chemistry Parameters: Albumin and Protein
Blood samples were collected to analyze clinical chemistry parameters including albumin and protein. Baseline is defined as Day 1 (Pre-Dose). Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline and at Day 2
Change From Baseline Values for Clinical Chemistry Parameters: Bilirubin, Direct Bilirubin and Creatinine
Blood samples were collected to analyze clinical chemistry parameters including bilirubin, direct bilirubin and creatinine. Baseline is defined as Day 1 (Pre-Dose). Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline and at Day 2
Change From Baseline Values for Clinical Chemistry Parameters: Calcium, Glucose, Potassium, Sodium and Urea
Blood samples were collected to analyze clinical chemistry parameters including calcium, glucose, potassium, sodium and urea. Baseline is defined as Day 1 (Pre-Dose). Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline and at Day 2
Number of Participants With Toxicity Grading 3 or Higher for Hematology Parameters
Blood samples were collected to measure the number of participants with toxicity grades higher than 3 or 4 for blood neurtophils and blood platelets.
Time frame: Up to 15 days
Number of Participants With Toxicity Grading 3 or Higher for Urinalysis Parameters
Urine samples were collected and specific gravity, potential of hydrogen (pH), glucose, protein, blood and ketones were analyzed by dipstick method.
Time frame: Up to 15 days
Number of Participants With Abnormal Findings During Physical Examinations
A complete physical examination included, at a minimum, assessments of the skin, cardiovascular, respiratory, gastrointestinal and neurological systems. Height and weight were also measured and recorded. A brief physical examination included, at a minimum, assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen). This analysis was planned but data was not captured in the database. Abnormal changes were captured as adverse events if they were clinically significant.
Time frame: Pre-dose up to 31 days prior to dosing
Total Unchanged Drug (Ae_total) and Amount of Drug Excreted in Urine in a Time Intervals (Ae (t1-t2) for Gepotidacin
Urine samples were collected from participants at indicated time points. Ae_total was calculated by adding all the fractions of drug collected over all the allotted time intervals. Ae (t1-t2) was the amount of drug excreted in urine in time intervals for predose, 0 to 6, 6 to 12, 12 to 24, 24 to 36, and 36 to 48 hours after dosing for participants with hepatic impairment; and predose, 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours for participants with normal hepatic function. It was calculated by multiplication of the urine concentration for a time interval and the length of this time interval.
Time frame: Pre-dose, 0-2 hours, 2-4 hours, 4-6 hours, 6-8 hours, 8-12 hours, 12-24 hours, 24-36 hours and 36-48 hours post-dose
Percentage of the Given Dose of Drug Excreted in Urine (Fe%)
Urine samples were collected from participants at indicated time points. Percentage of the given dose of drug excreted in urine was calculated as: (Ae_total divided by Dose) and multiplied by 100.
Time frame: Pre-dose, 0-2 hours, 2-4 hours, 4-6 hours, 6-8 hours, 8-12 hours, 12-24 hours, 24-36 hours and 36-48 hours post-dose
Renal Clearance (CLr) of Gepotidacin
Urine samples were collected from participants at indicated time points. Renal clearance for gepotidacin was calculated as Ae_total divided by AUC (0-t).
Time frame: Pre-dose, 0-2 hours, 2-4 hours, 4-6 hours, 6-8 hours, 8-12 hours, 12-24 hours, 24-36 hours and 36-48 hours post-dose
AUC(0-12) of Gepotidacin
Urine samples were collected from participants at indicated time points to evaluate AUC(0-12) PK parameter of gepotidacin.
Time frame: Pre-dose, 0-2 hours, 2-4 hours, 4-6 hours, 6-8 hours and 8-12 hours post dose
AUC(0-24) of Gepotidacin
Urine samples were collected from participants at indicated time points to evaluate AUC(0-24) PK parameter of gepotidacin.
Time frame: Pre-dose, 0-2 hours, 2-4 hours, 4-6 hours, 6-8 hours, 8-12 hours and 12-24 hours post dose
AUC(0-48) of Gepotidacin
Urine samples were collected from participants at indicated time points to evaluate AUC(0-48) PK parameter of gepotidacin.
Time frame: Pre-dose, 0-2 hours, 2-4 hours, 4-6 hours, 6-8 hours, 8-12 hours, 12-24 hours, 24-36 hours and 36-48 hours post dose
This was a Phase I, non-randomized, open-label, parallel-group, multi-center, two-part study that evaluated the pharmacokinetics, safety, and tolerability of a single 1500 milligrams (mg) oral dose of gepotidacin in participants with normal hepatic function and in participants with mild, moderate, and severe hepatic impairment.
| Milestone | Participants With Normal Hepatic Function | Participants With Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment |
|---|---|---|---|
| Started | 8 | 8 | 0 |
| Completed | 7 | 8 | 0 |
| Not completed | 1 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Milestone | Participants With Normal Hepatic Function | Participants With Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment |
|---|---|---|---|
| Started | 8 | 0 | 8 |
| Completed | 8 | 0 | 8 |
| Not completed | 0 | 0 | 0 |
Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate pharmacokinetic (PK) parameters. PK parameter population consist of all participants in the PK Population, for whom valid and evaluable PK parameters were derived. This population was used in the assessment and characterization of PK parameters.
| Hours*nanograms per milliliter | Participants With Normal Hepatic Function | Participants With Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment |
|---|---|---|---|
| Area Under the Plasma Concentration-time Curve (AUC) From Time Zero (Pre-dose) Extrapolated to Infinity (AUC[0-inf]) for Plasma Gepotidacin | 15894.7 ± 44.1 | 19505.7 ± 42.6 | 25415.5 ± 30.1 |
Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate PK parameters.
| Nanograms per milliliter | Participants With Normal Hepatic Function | Participants With Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment |
|---|---|---|---|
| Maximum Observed Concentration (Cmax) for Plasma Gepotidacin | 3196.8 ± 85.0 | 3913.7 ± 64.1 | 5541.8 ± 42.7 |
Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate PK parameters.
| Hours*nanograms per milliliter | Participants With Normal Hepatic Function | Participants With Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment |
|---|---|---|---|
| AUC From Time 0 to the Time of the Last Quantifiable Concentration (AUC [0-t]) for Plasma Gepotidacin | 15512.9 ± 45.8 | 19151.6 ± 43.4 | 25066.8 ± 30.5 |
Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate PK parameters.
| Hours | Participants With Normal Hepatic Function | Participants With Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment |
|---|---|---|---|
| Time to First Occurrence (Tmax) of Cmax for Plasma Gepotidacin | 3.000 (1.50 to 6.00) | 2.750 (2.50 to 4.00) | 2.250 (0.50 to 4.00) |
Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate PK parameters.
| Hours | Participants With Normal Hepatic Function | Participants With Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment |
|---|---|---|---|
| Lag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) for Plasma Gepotidacin | 0.50 (0.0 to 2.5) | 0.00 (0.0 to 1.0) | 0.00 (0.0 to 1.0) |
Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate PK parameters.
| Liters per hours | Participants With Normal Hepatic Function | Participants With Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment |
|---|---|---|---|
| Apparent Oral Clearance (CL/F) for Plasma Gepotidacin | 94.37 ± 44.1 | 76.90 ± 42.6 | 59.02 ± 30.1 |
Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate PK parameters.
| Liters | Participants With Normal Hepatic Function | Participants With Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment |
|---|---|---|---|
| Apparent Volume of Distribution of the Terminal Phase (Vz/F) for Plasma Gepotidacin | 1235.3 ± 57.5 | 944.7 ± 50.3 | 699.1 ± 41.7 |
Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate PK parameters.
| Per hour | Participants With Normal Hepatic Function | Participants With Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment |
|---|---|---|---|
| Terminal-phase Rate Constant (Lambda_z) for Plasma Gepotidacin | 0.07639 ± 14.9 | 0.08140 ± 12.3 | 0.08443 ± 15.2 |
Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate PK parameters.
| Hours | Participants With Normal Hepatic Function | Participants With Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment |
|---|---|---|---|
| Terminal Phase Half Life (t1/2) for Plasma Gepotidacin | 9.073 ± 14.9 | 8.515 ± 12.3 | 8.210 ± 15.2 |
Single 12-lead ECG was obtained in a semi-supine position after 5 minutes rest using an ECG machine. Safety Population consists of all participants who received at least 1 dose of study drug and had at least one postdose safety assessment. Number of participants with abnormal-clinically significant and abnormal-not clinically significant values has been presented. Absolute QTc Interval \>450 milliseconds (msec), absolute PR interval \<110 msec and absolute QRS interval \<75 msec was considered as clinically significant ECG findings.
| Participants | Participants With Normal Hepatic Function | Participants With Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment |
|---|---|---|---|
| 1.5 hours, not clinically significant | 1 | 6 | 3 |
| 1.5 hours, clinically significant | 0 | 0 | 0 |
| 2 hours, not clinically significant | 5 | 6 | 5 |
| 2 hours, clinically significant | 0 | 0 | 0 |
| 4 hours, not clinically significant | 6 | 6 | 5 |
| 4 hours, clinically significant | 0 | 0 | 0 |
| 8 hours, not clinically significant | 3 | 5 | 4 |
| 8 hours, clinically significant | 0 | 0 | 0 |
| 12 hours, not clinically significant | 2 | 4 | 2 |
| 12 hours, clinically significant | 0 | 0 | 0 |
| 24 hours, not clinically significant | 6 | 5 | 5 |
| 24 hours, clinically significant | 0 | 0 | 0 |
| 36 hours, not clinically significant | 2 | 5 | 4 |
| 36 hours, clinically significant | 0 | 0 | 0 |
| 48 hours, not clinically significant | 4 | 5 | 5 |
| 48 hours, clinically significant | 0 | 0 | 0 |
Vital signs were measured in a semi-supine position after 5 minutes rest. Baseline is defined as Day 1 (Pre-Dose). Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.
| Millimeters of mercury | Participants With Normal Hepatic Function | Participants With Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment |
|---|---|---|---|
| SBP, 1.5 hours | -10.4 ± 15.19 | -6.1 ± 11.86 | -3.8 ± 7.65 |
| SBP, 2 hours | -10.3 ± 10.99 | -7.5 ± 7.82 | -0.1 ± 11.96 |
| SBP, 4 hours | -6.2 ± 11.53 | -3.0 ± 8.85 | 0.5 ± 9.61 |
| SBP, 8 hours | -10.1 ± 9.64 | -0.5 ± 8.25 | -2.9 ± 6.79 |
| SBP, 12 hours | -5.1 ± 9.43 | -0.6 ± 8.00 | -1.9 ± 12.78 |
| SBP, 24 hours | -9.8 ± 15.75 | -6.6 ± 11.58 | -4.9 ± 8.10 |
| SBP, 36 hours | -7.3 ± 13.98 | 2.0 ± 8.86 | -2.6 ± 12.64 |
| SBP, 48 hours | -6.7 ± 13.08 | -10.6 ± 19.38 | -5.3 ± 14.04 |
| DBP, 1.5 hours | -6.8 ± 8.84 | -3.5 ± 7.05 | 1.1 ± 9.25 |
| DBP, 2 hours | -6.4 ± 6.13 | -5.1 ± 6.29 | 2.4 ± 7.17 |
| DBP, 4 hours | -3.8 ± 7.12 | -0.9 ± 6.75 | 3.4 ± 6.19 |
| DBP, 8 hours | -7.0 ± 4.80 | -2.9 ± 5.51 | -0.8 ± 7.69 |
| DBP, 12 hours | -5.4 ± 3.64 | -3.1 ± 6.24 | 1.9 ± 7.26 |
| DBP, 24 hours | -8.4 ± 8.69 | -3.4 ± 12.00 | -1.0 ± 10.68 |
| DBP, 36 hours | -9.3 ± 7.26 | -1.3 ± 5.50 | -1.1 ± 6.33 |
| DBP, 48 hours | -6.6 ± 8.38 | 0.9 ± 11.32 | 0.8 ± 6.18 |
Vital signs was measured in a semi-supine position after 5 minutes rest. Baseline is defined as Day 1 (Pre-Dose). Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.
| Beats per minute | Participants With Normal Hepatic Function | Participants With Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment |
|---|---|---|---|
| 1.5 hours | 0.3 ± 7.47 | 0.6 ± 9.86 | -0.6 ± 6.50 |
| 2 hours | -0.8 ± 7.98 | -0.1 ± 10.20 | 0.8 ± 5.60 |
| 4 hours | -3.7 ± 8.79 | 1.4 ± 4.44 | 0.1 ± 6.77 |
| 8 hours | -1.3 ± 7.91 | 2.6 ± 4.90 | 1.0 ± 4.93 |
| 12 hours | 3.9 ± 12.23 | 4.8 ± 3.58 | 5.1 ± 7.26 |
| 24 hours | -4.3 ± 6.78 | -1.1 ± 6.64 | -2.0 ± 8.12 |
| 36 hours | 3.8 ± 9.76 | 3.8 ± 3.20 | 2.4 ± 9.68 |
| 48 hours | -0.7 ± 3.94 | 2.8 ± 7.19 | -0.9 ± 6.56 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgment.
| Participants | Participants With Normal Hepatic Function | Participants With Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment |
|---|---|---|---|
| Any Non-SAE | 3 | 2 | 4 |
| Any SAE | 1 | 0 | 0 |
Blood samples were collected to measure the number of participants with toxicity grades higher than 3 or 4, for urea, Creatine kinase (CK), creatinine, glucose, sodium, potassium, calcium, Aspartate Aminotransferase, (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) levels, total and direct bilirubin, total protein, and albumin.
| Participants | Participants With Normal Hepatic Function | Participants With Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment |
|---|---|---|---|
| Number of Participants With Toxicity Grading 3 or Higher for Clinical Chemistry Parameters | 0 | 1 | 6 |
Blood samples were collected to analyze clinical chemistry parameters including: ALT, ALP, AST and CK. Baseline is defined as Day 1 (Pre-Dose). Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.
| International units per liter | Participants With Normal Hepatic Function | Participants With Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment |
|---|---|---|---|
| ALT, Day 2 | -2.1 ± 5.90 | -0.1 ± 4.19 | -3.7 ± 6.59 |
| ALP, Day 2 | -1.3 ± 7.98 | -4.4 ± 5.21 | -5.2 ± 4.36 |
| AST, Day 2 | -1.8 ± 2.59 | -1.5 ± 4.31 | -7.8 ± 10.59 |
| CK, Day 2 | -52.9 ± 57.31 | -36.4 ± 35.73 | -32.3 ± 79.05 |
Blood samples were collected to analyze clinical chemistry parameters including albumin and protein. Baseline is defined as Day 1 (Pre-Dose). Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.
| Grams per liter | Participants With Normal Hepatic Function | Participants With Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment |
|---|---|---|---|
| Albumin, Day 2 | -1.3 ± 2.35 | -0.4 ± 1.60 | -1.7 ± 2.80 |
| Protein, Day 2 | -0.9 ± 4.26 | 0.8 ± 2.82 | -3.5 ± 5.72 |
Blood samples were collected to analyze clinical chemistry parameters including bilirubin, direct bilirubin and creatinine. Baseline is defined as Day 1 (Pre-Dose). Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.
| Micromoles per liter | Participants With Normal Hepatic Function | Participants With Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment |
|---|---|---|---|
| Bilirubin, Day 2 | -2.470 ± 4.6131 | -1.924 ± 4.9592 | -7.695 ± 12.6932 |
| Creatinine, Day 2 | -3.2413 ± 5.97927 | 7.6245 ± 15.89752 | -0.4420 ± 4.83379 |
| Direct bilirubin, Day 2 | -0.3230 ± 0.71250 | -0.5771 ± 0.89060 | -1.8525 ± 2.71759 |
Blood samples were collected to analyze clinical chemistry parameters including calcium, glucose, potassium, sodium and urea. Baseline is defined as Day 1 (Pre-Dose). Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.
| Millimoles per liter | Participants With Normal Hepatic Function | Participants With Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment |
|---|---|---|---|
| Calcium, Day 2 | -0.00831 ± 0.065033 | -0.01623 ± 0.059119 | -0.05488 ± 0.092641 |
| Glucose, Day 2 | -0.08016 ± 0.514103 | 0.04855 ± 0.755546 | -0.79563 ± 2.183639 |
| Potassium, Day 2 | 0.01 ± 0.481 | 0.35 ± 0.307 | 0.02 ± 0.337 |
| Sodium, Day 2 | -0.4 ± 1.67 | 0.6 ± 2.33 | 0.7 ± 1.97 |
| Urea, Day 2 | 0.1983 ± 0.92942 | 0.4909 ± 1.29336 | 0.2975 ± 0.57194 |
Blood samples were collected to measure the number of participants with toxicity grades higher than 3 or 4 for blood neurtophils and blood platelets.
| Participants | Participants With Normal Hepatic Function | Participants With Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment |
|---|---|---|---|
| Number of Participants With Toxicity Grading 3 or Higher for Hematology Parameters | 0 | 0 | 2 |
Urine samples were collected and specific gravity, potential of hydrogen (pH), glucose, protein, blood and ketones were analyzed by dipstick method.
| Participants | Participants With Normal Hepatic Function | Participants With Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment |
|---|---|---|---|
| Number of Participants With Toxicity Grading 3 or Higher for Urinalysis Parameters | 0 | 0 | 0 |
A complete physical examination included, at a minimum, assessments of the skin, cardiovascular, respiratory, gastrointestinal and neurological systems. Height and weight were also measured and recorded. A brief physical examination included, at a minimum, assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen). This analysis was planned but data was not captured in the database. Abnormal changes were captured as adverse events if they were clinically significant.
No measurements were reported for this outcome.
Urine samples were collected from participants at indicated time points. Ae_total was calculated by adding all the fractions of drug collected over all the allotted time intervals. Ae (t1-t2) was the amount of drug excreted in urine in time intervals for predose, 0 to 6, 6 to 12, 12 to 24, 24 to 36, and 36 to 48 hours after dosing for participants with hepatic impairment; and predose, 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours for participants with normal hepatic function. It was calculated by multiplication of the urine concentration for a time interval and the length of this time interval.
| Milligrams | Participants With Normal Hepatic Function | Participants With Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment |
|---|---|---|---|
| Ae_total, n=6, 6, 6 | 127.67 ± 63.552 | 191.39 ± 84.368 | 325.31 ± 124.273 |
| Ae (0-2), n=8, 0, 0 | 5.82 ± 7.838 | — | — |
| Ae (2-4), n=9, 0, 0 | 55.53 ± 55.735 | — | — |
| Ae (4-6), n=9, 0, 0 | 28.79 ± 19.702 | — | — |
| Ae (0-6), n=0, 7, 8 | — | 144.24 ± 104.112 | 199.28 ± 103.407 |
| Ae (6-8), n=9, 0, 0 | 18.67 ± 8.371 | — | — |
| Ae (6-12), n=0, 7, 8 | — | 60.53 ± 35.231 | 112.65 ± 93.439 |
| Ae (8-12), n=9, 0, 0 | 16.21 ± 7.056 | — | — |
| Ae (12-24), n=7, 6, 7 | 11.15 ± 6.007 | 12.72 ± 7.265 | 23.27 ± 17.258 |
| Ae (24-36), n=8, 7, 7 | 6.62 ± 4.675 | 8.44 ± 3.914 | 12.78 ± 6.869 |
| Ae (36-48), n=6, 8, 7 | 3.71 ± 1.845 | 4.59 ± 3.512 | 6.04 ± 2.909 |
Urine samples were collected from participants at indicated time points. Percentage of the given dose of drug excreted in urine was calculated as: (Ae_total divided by Dose) and multiplied by 100.
| Percentage of drug | Participants With Normal Hepatic Function | Participants With Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment |
|---|---|---|---|
| Percentage of the Given Dose of Drug Excreted in Urine (Fe%) | 8.51 ± 4.237 | 12.76 ± 5.625 | 21.69 ± 8.285 |
Urine samples were collected from participants at indicated time points. Renal clearance for gepotidacin was calculated as Ae_total divided by AUC (0-t).
| Liters per hour | Participants With Normal Hepatic Function | Participants With Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment |
|---|---|---|---|
| Renal Clearance (CLr) of Gepotidacin | 8.18 ± 3.209 | 9.45 ± 2.710 | 12.46 ± 3.911 |
Urine samples were collected from participants at indicated time points to evaluate AUC(0-12) PK parameter of gepotidacin.
| Hours*micrograms per milliliter | Participants With Normal Hepatic Function | Participants With Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment |
|---|---|---|---|
| AUC(0-12) of Gepotidacin | 1201 ± 1033.5 | 3030 ± 2245.5 | 4771 ± 4678.3 |
Urine samples were collected from participants at indicated time points to evaluate AUC(0-24) PK parameter of gepotidacin.
| Hours*micrograms per milliliter | Participants With Normal Hepatic Function | Participants With Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment |
|---|---|---|---|
| AUC(0-24) of Gepotidacin | 1269 ± 1040.4 | 2925 ± 1868.3 | 5807 ± 5151.0 |
Urine samples were collected from participants at indicated time points to evaluate AUC(0-48) PK parameter of gepotidacin.
| Hours*micrograms per milliliter | Participants With Normal Hepatic Function | Participants With Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment |
|---|---|---|---|
| AUC(0-48) of Gepotidacin | 1394 ± 1252.4 | 3547 ± 1667.9 | 5035 ± 4695.6 |
Collected over Non-serious AEs and SAEs were collected from the start of the treatment up to 15 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Participants With Normal Hepatic Function | 1/9 (11.1%) | 1/9 (11.1%) | 3/9 (33.3%) |
| Participants With Moderate Hepatic Impairment | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Participants With Severe Hepatic Impairment | 0/8 (0%) | 0/8 (0%) | 4/8 (50%) |
| Event | Participants With Normal Hepatic Function | Participants With Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment |
|---|---|---|---|
| DeathGeneral disorders | 1/9 | 0/8 | 0/8 |
| Event | Participants With Normal Hepatic Function | Participants With Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/9 | 2/8 | 2/8 |
| NauseaGastrointestinal disorders | 0/9 | 0/8 | 1/8 |
| HeadacheNervous system disorders | 0/9 | 1/8 | 1/8 |
| LeukopeniaBlood and lymphatic system disorders | 0/9 | 0/8 | 1/8 |
| Wrist fractureInjury, poisoning and procedural complications | 0/9 | 1/8 | 0/8 |
| Decreased appetiteMetabolism and nutrition disorders | 0/9 | 0/8 | 1/8 |
| Age, Continuous(Years) | Participants With Normal Hepatic Function | Participants With Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment | Total |
|---|---|---|---|---|
| Mean | 59.8 ± 5.70 | 62.5 ± 7.19 | 58.1 ± 6.15 | 60.1 ± 6.34 |
| Sex: Female, Male(Participants) | Participants With Normal Hepatic Function | Participants With Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment | Total |
|---|---|---|---|---|
| Female | 1 | 1 | 0 | 2 |
| Male | 8 | 7 | 8 | 23 |
| Race/Ethnicity, Customized(Participants) | Participants With Normal Hepatic Function | Participants With Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment | Total |
|---|---|---|---|---|
| Asian - Central/South Asian Heritage | 0 | 0 | 1 | 1 |
| African American/African Heritage | 3 | 0 | 0 | 3 |
| White - White/Caucasian/European Heritage | 6 | 8 | 7 | 21 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study is available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (copy the URL below to your browser)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Jun 2018 to primary completion in Dec 2018, 6 months.
Results were first posted in Dec 2019, 11 months after primary completion.
Of 52 industry-sponsored phase 1 interventional studies under Bacterial Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 6 months is below that.
Counting every sponsor, half of 67 studies reached it within 9 months; a quarter within 4 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gepotidacin